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Abstract
An experiment involving active immunotherapy of leukemia in mice and its extension to human patients with 
chronic lymphocytic leukemia is described. First, anticancer activation of the immune system, how it is achieved, 
and observations of the central blockade of the immune system in leukemia are discussed. Clinical results of 
antileukemia immune activation are then presented, along with a description of new attempts to remove the 
immune checkpoint blockade. Personal observations are presented on possible further steps to achieving more 
effective active immunotherapy of cancer. (Folia Histochemica et Cytobiologica 2018, Vol. 56, No. 1, 1–10)
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Introduction
Immune responses to mutation events within cells 
leading to cancer or microbial pathogens are orga-
nized by the interaction between cells of the innate 
and adaptive parts of the immune systems. One aspect 
of the adaptive immune system is its capacity to re-
member previous encounters with the same antigen. 
This could serve as a basis for constructing anticancer 
vaccines. The main theoretical basis of this therapy is 
the fact that almost every cell of the 1016 cells in the 
human body is monitored by the immune system, 
and virally infected or mutated cells are recognized 
and removed. The hypothesis suggests that further 
activation of the immune system would result in more 
effective removal of mutated cancer cells expressing 
tumor antigens (now called neoantigens) that are not 
present in the normal cells. They are recognized by 
T cells differentiated in the thymus against the tumor 
neoantigens. Vaccination with tumor antigens present 
within cancer cells should increase the activation of 
actually present anti-tumor T-cells and lead to the 
activation of new ones, as the collection of tumor 
antigens changes during development of the tumor. 
An experiment on an animal model was performed 
on DBA/2 mice treated with leukemia L1210 cells. The 
leukemia cells were cultured in vitro, essentially as de-
scribed in the National Cancer Institute Program [1], 
and after implanting in the healthy animals, an acute 
leukemia process developed. It was assumed that 
the leukemia cells were syngeneic with DBA/2 mice, 
so the L1210 cell implantation was not an allogenic 
transplant. That was first tested by comparing MHC 
class I of the DBA/2 mice lymphocytes with L1210 
cells [2], confirming the syngeneic character of the 
leukemia cells (Table 1). In the model, activation of 
the mouse immune system should target the L1210 
leukemia cells.
The immune system may theoretically be activat-
ed by implanting a large quantity of leukemia cell 
antigens. The genetic instability of cancer cells is 
well known [3, 4], and so the best collection of L1210 
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antigens would be from within the leukemia cells 
themselves. This hypothesis suggested induction of 
T cell responses to the mouse leukemia cells antigens 
now called neoantigens which are absent in the normal 
cells [5]. Theoretically, a tumor surgically removed 
from a patient would constitute the best source of 
tumor antigens. However, the malignant antigenic 
tumor cells cannot be directly applied to induce anti-
cancer immune responses. Moreover, dead, necrotic 
cells cannot be used to induce anticancer responses, 
because they are immediately recognized and re-
moved by local inflammatory processes. Another ar-
gument against use of necrotic cells is that they release 
K+ ions, which has been found to suppress the activity 
of the immune system’s T cells [6]. Therefore, in the 
proposed animal model, leukemia antigens were 
applied in the form of leukemia cells with induced 
apoptosis. The induction of apoptosis in cells blocks 
their proliferation; however, the commencement of 
the apoptotic process is delayed in many cells. The cell 
apoptotic process begins several hours, or even some 
days, after induction [7–9]; however, the apoptotic 
process itself takes only about 2 h to proceed. A cell in 
apoptosis will be recognized by surrounding cells and 
immediately removed by phagocytosis. It appears that 
leukemia cells with induced apoptosis are a long-term 
antigen stimulating system that functions within days, 
without inducing an inflammatory response [10, 11]. 
Anticancer activation of the immune system
The first experimental test of the antigen properties 
of the system was in DBA/2 mice vaccinated with 
various doses of apoptosis-induced L1210 leukemia 
cells. It was expected that implantation of apoptotic 
cells would delay leukemia growth in the vaccinated 
mice. Apoptosis in L1210 cells was induced in vitro 
by treatment with cyclophosphamide or mafosfamide 
(a derivative of cyclophosphamide) (L1210CY or 
L1210Maf cells). The in vitro treatment of cells with 
cyclophosphamide or mafosfamide blocked the mi-
totic cycle within the cells, which were then used for 
vaccinating the mice. One week later, the mice were 
implanted with 103 malignant L1210 leukemia cells in 
the logarithmic phase of growth [12]. Mice vaccinated 
with 105 L1210CY cells before the implantation of 
malignant L1210 cells survive the malignant leukemia 
significantly longer than mice not vaccinated, or vac-
cinated with dead leukemia cells (Table 2) [12]. This 
result suggests that the apoptotic L1210 cells are an 
effective antileukemia antigen. The effect was immu-
nologically specific, as it did not prolong the survival 
of mice with malignant L-1 sarcoma cells. 
In the next step of the experiment, we proceeded 
into the treatment of mice with already growing 
malignant leukemia [13]. The mice were intraperi-
toneally inoculated with 10 malignant L1210 leu-
kemia cells, and their survival of the leukemia was 
observed. We found that i.p. inoculated L1210 cells 
induced the death of mice in an average of 12.5 days 
(median survival time; MST), while i.p. injection of 
106 or 107 apoptotic L1210Maf cells at days 0, 3, 6, 
9, and 12 from start of the leukemia led to an MST 
of 13.5 days (Table 3). The vaccination was there-
fore ineffective over a period shorter than the full 
immunological response against the fast-growing 
leukemia. In order to prolong the survival of leu-
kemic mice inoculated with malignant L1210 cells, 
chemotherapy with cyclophosphamide (100 mg/kg) 
was administered i.p. at day 8, which resulted in a 
prolongation of the survival period to 19 days. When 
the mice treated with chemotherapy were vaccinated 
i.p. with 107 apoptotic L1210Maf cells at 0, 3, 6, 9, and 
Table 1. Leukemia L1210 cells are syngeneic with the lymph 
node cells of DBA/2 mice. Result of the reaction with various 
antibodies against H-2 alloantigens [2]
Antibody Cytotoxic titer
L1210  
cells
Lymph-node cells*
anti H-2Ka  > 80  
(positive)
> 160
anti H-2Dd  > 160  
(positive)
> 160
anti H-2Kb 0  
(negative)
 > 160  
(negative control)
anti H-2Db 0  
(negative)
 > 160  
(negative control)
*Lymphocytes taken from a strain of mouse of specified haplotype.
Table 2. Survival of mice with implanted malignant L1210 
cells (103 per animal) one week earlier vaccinated with 
apoptotic or dead L1210 cells, compared to unvaccinated 
control animals [12]
Number of cells No. of animals MST days Range, days
Control (-L1210CY) 58 20 18–22
L1210 dead, 105 10 19 17–21
L1210CY 103 10 18 14–22
L1210CY 104 10 32 20–51
L1210CY 105 10 66* 32–135
MST — Median Survival Time. *Statistically significant difference com-
pared to unvaccinated control, p < 0.05.
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12 days (as described before), the MST was 25 days 
(28.3% mice survival, 17 of 60). These leukemic mice 
lived for 100 days or more from the time of inoculation 
with malignant cells. A 100-day survival period of mice 
can be taken as recovery of animals from malignant 
leukemia; most mice were observed for 2 years. The 
success rate could be increased to 53% (16 of 30) by 
vaccination of the leukemia-inoculated mice with 107 
apoptotic L1210Maf cells given intraperitoneally and 
subcutaneously, and additional BCG (1 mg/mice) in-
oculation further increased the rate to 60% (6 of 10) 
of the leukemia-recovered animals. Thus, the ex-
periment demonstrated the possibility of successful 
treatment of acute leukemia in an animal model by 
activation of the immune system [13] and as shown 
by further tests, even when cells were resistant to the 
cytoplasmic agents [14]. It can be suggested that, using 
an appropriate vaccination and additional cyclophos-
phamide chemotherapy, the number of antileukemia 
lymphocyte clones could be significantly increased 
to effectively attack the malignant leukemia cells in 
the mice. 
Leukemia blockade of the immune system
The observation that only some of the vaccinated 
leukemic mice recovered suggests that the positive 
outcome was blocked by some mechanism in the 
nonrecovered animals. We thus decided to check 
the status of the thymus in the leukemic mice, in 
cooperation with HJ Seidel of the Department of 
Clinical Physiology and Occupational Medicine, 
University of Ulm, Germany. The plan was to test 
thymocyte differentiation in vivo in DBA/2 mice with 
L1210 leukemia. Within the first 3–6 days after i.p. 
implantation of 106 L1210 cells, we found profound 
changes in thymocyte subpopulations. Microscope ob-
servations clearly showed that leukemia significantly 
altered the differentiation of T cells, centrally blocking 
the immunological response to malignant cells [15]. 
Shortly thereafter, we repeated the thymocyte test in 
leukemic animals and examined changes in thymocyte 
subpopulations by flow cytometry; the results of the 
observations agreed well with the microscopic obser-
vations (Table 4) [16]. 
Table 3. Chemoimmunotherapy of L1210 leukemia in mice model [13] 
Group of mice Leukemia CY BRM L1210 Maf 
Cells
MST (range) 
(Survivors/total)
1 + – – – 12.5 (12.2–12.8)
(0/54)
2 + – – 106 i.p. 13.5 (12.3–14.8)
(0/10)
3 + – – 107 i.p. 12.5 (11.6–13.4)
(0/10)
4 + + – – 19.0 (18.5–19.5)a
(3/56)
5 + + – 106 i.p. 27.0 (22.6–32.3)b
(6/20)b
6 + + – 107 i.p. 25.0 (23.5–26.6)b
(17/60)c
7 + + – 107 i.p. + s.c. > 100
(16/30)de
8 + + + 107 i.p. + s.c. > 100
(6/10)b
Leukemia: each mouse received 10 malignant L1210 cells i.p. at day 0. CY: 100 mg/kg of cyclophosphamide was injected i.p. eight days after L1210 
leukemia challenge. BMR: BCG (1 mg/mouse = 3 × 106 viable bacilli) were injected i.p. on days 0, +3, +6, +9, +12 after L1210 leukemia challenge. 
L1210 Maf: the cells were injected on days 0, +3, +6, +9, +12 after L1210 leukemia challenge. ap < 0.05 as compared with group 1; bp < 0.05 as 
compared with group 4; cp < 0.01 as compared with group 4; dp < 0.001 as compared with group 4; ep < 0.05 as compared with group 6.
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In summary, we determined the conditions nec-
essary to activate the immune system using leukemia 
apoptotic cells, in order to achieve effective recovery 
from leukemia in mice. These were (i) small mass 
(number) of leukemia cells, and (ii) activation of the 
immune system of mice with apoptotic leukemia cells 
containing neoantigens.
Immune monitoring of cells  
in the human body
Human lymphocytes regularly monitor the amino acid 
sequence of cytoplasmic and nuclear proteins within 
cells. The knowledge of these mechanisms began with 
experiments on the presence of proteinases within 
normal cells. The presentation of intracellular protein 
structure to cells of the immune system is associated 
with their degradation to peptides. These peptides 
are then associated with major histocompatibility 
complex (MHC) class I molecules, and the peptides 
of this complex are presented to lymphocytes on the 
surface of each cell (Fig. 1). The peptides are usually 
8-mer to 12-mer peptides, produced within the pro-
teasome [17–19]. Peptide aldehydes that inhibit major 
peptidase activities of the 20S and 26S proteasomes 
are shown to reduce the degradation of protein and 
ubiquitinated protein substrates. These compounds 
inhibit the degradation of abnormal (and also normal) 
proteins in intact cells, and may be used to test the 
importance of the proteasome in antigen presenta-
tion. Blockage of proteasomal activity within cells 
leads to apoptosis. 
In our experiment, the proteasomal protease active 
within leukemia L1210 cells was tested by its inhibition 
using specific chymotrypsin inhibitor. Treatment of 
L1210 cells with inhibitor induced apoptosis (Fig. 2) 
[20]. The proteases are thus referred to as chymot-
rypsin-like (ChTr) proteases; they were present and 
active in the proteasomes of L1210 cells. Similar ChTr 
proteases have been observed in the other cancer cells, 
as well as in the normal cells. The ChTr protease of 
the type present in proteasomes was isolated and 
purified, and its properties in normal mast cells have 
Table 4. Subpopulations of thymocytes in leukemia-bearing mice or normal mice at different days after i.p. inoculation of 
106 L1210 malignant cells [15, 16]
Mice Subpopulation of thymocytes, percentage*
L3T4+Lyt 2+ L3T4+Lyt 2– L3T4–Lyt 2+ L3T4–Lyt 2– 
Normal, n = 7 78.0 ± 3.8 10.7 ± 2.0 5.0 ± 1.0 6.6 ± 1.8
L1210, 2 d., n = 2 73.0 ± 2.8 14.0 ± 1.4 7.0 ± 0 5.5 ± 0.7
L1210, 3 d., n = 5 71.6 ± 5.0 13.8 ± 1.9b 6.8 ± 0.4a 7.8 ± 2.8
L1210, 5 d., n = 4 62.0 ± 14.9b 19.3 ± 7.2 9.3 ± 2.1a 9.5 ± 5.4
L1210, 6 d., n = 6 48.3 ± 20.0b 25.2 ± 9.0 11.2 ± 5.3b 15.8 ± 7.8b
*Mean values ± SD; n = number of animals in the group, difference as compared with normal mice; asignificant at p < 0.01; bsignificant at p < 0.05.
Figure 1. Schematic presentation of the mechanism of pro-
tein antigen processing in the proteasome and endosome 
and peptide presentation with MHCs in most cells in the 
human body. The proteasome-processed protein fragments 
are transported to the endoplasmic reticulum and bound to 
MHC class I, while endosome processed proteins are bound 
to MHC class II. Protein fragments with MHC are transport-
ed to the surface of cell. However, proteins from apoptotic 
cells or their fragments, phagocytosed by the dendritic cells 
(DC), are released from the endosome to cytoplasm, where 
they are processed in the proteasome and bound to MHC 
class I before being presented on the cell surface. (- - -) 
pathway of antigens in the dendritic cell. TAP — transport 
associated processing; ER — endoplasmic reticulum.
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been described [21]. It is well known that the 26S 
proteasome is a multimeric complex consisting of a 
centrally located 20S core catalytic complex flanked 
by 19S regulatory subunits. The 20S complex contains 
b rings with three active enzymatic sites of distinct 
substrate specificities: chymotrypsin-like on the b5 
subunit, trypsin-like on the b2 subunit, and caspase-
like on the b1 subunit [22].
Within the immune system, there is an active 
specialized type of cells called myeloid dendritic cells 
(mDCs), which have some additional functions in 
the presentation of peptide antigens. These mDCs 
have the additional property that their endocytotic 
membrane is capable of transporting part of the ex-
tracellular endocytosed proteins to the cytoplasm [23, 
24], where they are processed by proteasomes of the 
phagocytosing cell. The phagocytosed extracellular 
protein peptides are then transported to the endo-
plasmic reticulum and presented to T lymphocytes 
with MHC class I on their cell surface. In this way, 
the exogenous antigens access the cytosol of mDC and 
are processed for presentation via the same pathway 
as described for conventional MHC class I restricted 
cytosolic protein antigens. 
mDCs differentiate following phagocytosis of 
apoptotic cells and translocate to the lymph nodes 
[25, 26], where there are the optimal conditions for 
the presentation of cancer/leukemia antigens to 
naïve T cells constantly flowing (translocating) in 
the lymph. It has been described that mDCs remain 
and function within the lymph nodes over 2–3 weeks. 
This mean of presenting of mDCs is referred to as 
the crosspresentation of antigens, because with MHC 
class I not only are own-cell proteins presented, but 
so are the phagocytosed proteins of the apoptotic 
leukemia cells. We therefore suggest that the de-
scribed recovery from leukemia of the mice treated 
with apoptotic L1210 leukemia cells was possible due 
to this process of crosspresentation of antigens in the 
phagocytosed cells by mDCs. 
Clinical attempts to activate  
antileukemia immunity
The experiment in mice, with its conclusion that it 
is possible to activate the immune system to cure 
leukemia, was the basis for performing similar 
clinical tests in patients. Human chronic lympho-
cytic leukemia (B-CLL) is a hematologic neoplasm 
characterized by accumulation of a subpopulation of 
B-lymphocytes CD19+CD5+. The disease typically 
occurs over the age of 50 [27]. The clinical course of 
B-CLL is highly variable. When we first discussed the 
clinical experiment, the therapy of patients with the 
stable disease was limited to watching and waiting, 
coupled with treatment of disease-related symptoms: 
progressive marrow failure (anemia, thrombocytope-
nia), autoimmune complications, massive splenomeg-
aly, lymphadenopathy, and infectious complications. 
Very precise prognostic diagnosis based on cytometric 
Figure 2. Inhibition of chymotrypsin-like protease in L1210 leukemia cells induces apoptosis of cells. Cells analyzed by the 
propidium iodide (PI) method in a control sample (A) and in the sample incubated for 24 h in the presence of 500 nM PSI 
(chymotrypsin inhibitor) (B). Plot axes: FSC vs. FL2 (PI on y-axis). R2 living cells, R3 apoptotic cells, R4 necrotic cells [20]. 
A B
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analysis was required [28, 29]. Chemotherapy and 
passive immunotherapy with monoclonal antibodies 
were also possible treatments. About 15 years ago, it 
was established that rituximab, a chimeric anti-CD20 
monoclonal antibody, is effective when administered 
with chemotherapy. It was shown that rituximab sig-
nificantly improves the outcome of both untreated 
and previously treated B-CLL patients [30–33]. Some 
other antibodies, such as ofatumumab, are also ad-
vised clinically [34]. 
The slow progress of B-CLL in some patients pro-
vides time for active immunotherapy. We therefore 
proposed to follow the treatment described earlier. 
Patients’ consent was obtained, as was the agreement 
of the Ethical Commission at the School of Medicine, 
Lublin. It was assumed that B-CLL antigens could 
be crosspresented by mDCs. Preliminary results 
were presented in 2003 [35]. The clinical test was 
based on the use of the patient’s CLL autologous 
apoptotic B-cells as a vaccine. The cells contained 
actual leukemia neoantigens of mutated proteins, 
with contents likely differing in different patients. 
We first performed tests in vitro, using gamma-irra-
diation doses to induce apoptosis in peripheral blood 
mononuclear cells (MNC) isolated from patients with 
B-CLL. The optimal radiation dose for inducing leu-
kemia cells apoptosis in vitro was found to be 1000 Gy 
for 1 hour [8]. In different irradiated MNCs, the 
apoptosis process started hours or even days later, as 
shown by in vitro tests, which may be evidence of the 
variability of leukemia cells. The irradiated cells were 
given s.c. in the arm region near the lymph nodes. 
As irradiated cells begun to undergo the apoptotic 
process within few days, the procedure was repeat-
ed once a week, 11–12 times, to keep the leukemia 
antigen constantly exposed to the patient’s immune 
system for a prolonged time. The procedure did not 
induce significant adverse effects, except for some 
small redness of the skin at the injection site, and 
sometimes a temperature rise of 1oC on the following 
day. Long-term observation of patients over a number 
of years did not disclose any adverse problems related 
to the vaccination [36, 37]. 
One positive outcome for patients during the 
vaccination, and for some 2–3 months longer, was a 
lower level of leukocytosis and lymphocytosis than 
they started with (Fig. 3). However, some patients 
(7 of 17) did not respond to the treatment, for which 
we have not explanation (Fig. 4). The most important 
difference, compared to the results of the animal in 
vivo experiment, was that there was no cure for pa-
tients with B-CLL. This could be expected as, during 
the long period of B-CLL development, the general 
mass of leukemia cells becomes large and the patient’s 
immune system is constantly paralyzed. In our mice, 
L1210 leukemia was treated within a short time, and 
the leukemia cell mass (the number of L1210 cells) 
remained low. 
Figure 3. Leukocyte (WBC) and lymphocyte trend curves of a patient with B-CLL treated with irradiated leukemia cell 
vaccines from the time of initial diagnosis during immunotherapy to twelve months after the end of vaccination (patient 
from hematological improvement group) [37]. Arrows — time of vaccine injections.
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The following conclusions can be drawn from the 
clinical experiment: applied vaccination treatment 
cannot cure patient with B-cell chronic lymphocytic 
leukemia; however, in about two out of three patients, 
a delay in disease progression was observed for some 
period. These can be beneficial for the patient, as the 
well-known hematological problems (anemia, throm-
bocytopenia) are blocked for some time. New clones of 
T lymphocytes directed against leukemia cells enlarge, 
and preserve the activation markers for a long time, as 
has been shown with cytometric analysis of peripheral 
blood leukocytes of vaccinated patients. However, 
the activated T cells are cytotoxic to the recognized 
leukemia cells only for a short period of time (Fig. 5), 
as their costimulation is then blocked by the expres-
sion of checkpoint-blocking proteins such as CTLA4 
(cytotoxic T-lymphocyte associated protein 4) or 
PD-1 (programmed cell death-1). Also, as part of 
the immune response in vaccinated patients, Treg 
cell clones are also rapidly enlarged and activated. 
The blocking of the T cell responses is probably the 
natural, physiological process that prevents long-term 
allergic activation. The vaccination did not lead to any 
undesired processes in patients, even after observa-
tion of some of them for 14 years.
Figure 5. Schematic presentation of the activation of T 
lymphocytes through recognition of the antigen presented 
with MHC class I and costimulation of the activated T cell 
necessary for exerting a cytotoxic effect on the target cell. 
There are two processes necessary for effector function of 
the T cell: recognition of the presented peptide antigen, and 
costimulation by interaction between CD80CD86 and CD28 
on the lymphocyte. After some time, the checkpoint blocking 
protein CTLA4T appears on the T cell surface. Interaction 
of CTLA4 on the T cell with CD80CD86, however, blocks 
effector function. Moreover, CTLA4 has higher affinity to 
the CD80/CD86 than to CD28.
Figure 4. Summary of the vaccination results of 17 patients: 
(A) five responded with lower WBC (0.29), (B) five stabilized 
the increase of WBC (0.29) and (C) seven did not respond 
(0.41) [37]. 
A
B
C
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Anticancer immune activation:  
More recent attempts
The observation of patients with different cancer 
types now suggests some additional general con-
clusions. Immunological therapy in patients with 
cancer is rather of the passive type, involving the 
application of monoclonal antibodies. The chem-
otherapeutic pathway is intended to decrease the 
mass and lower the number of cancer cells, as well 
to block some known cellular regulatory processes. 
The active immunotherapy described here, based as 
it is on the activation of the immune T cells, involves 
recognizing the neoproteins of the mutated cancer 
cells. This should lead to better recognition of altered, 
mutated cells, allowing them to be more efficiently 
removed. This works for a period of time, but is then 
blocked by the expression of checkpoint blockers 
on activated lymphocytes [38–41]. In B-CLL, it can 
thus be proposed that complex associated active 
immunotherapy be used in conjunction with passive 
immunotherapy (rituximab), followed by antibodies 
that block the checkpoint blockers — e.g., directed 
at CTLA4 (ipilimumab) or PD-1 and its ligands [42, 
43]. Promising clinical attempts to block the check-
point blockers are now underway, so the application 
of complex associated active immunotherapy may 
soon appear as a promising therapeutic approach. 
Long-term observations of both healthy individ-
uals and B-CLL patients suggest that an important 
role is played in cancer immunity by the T lympho-
cyte subpopulations discussed above (CD3+CD4+ 
and CD3+CD8+) recognizing infected or mutated 
cytoplasmic proteins within the cells. Mammalian 
T cells monitor the proteome of most cells; however, 
the lymphocyte subpopulation called NKT cells rec-
ognize another group of compounds in cells (lipids 
and glycolipids) and appear to be very important 
for the normal functioning and regulation of the 
immune system [44–46]. The activation of NKT cells 
is probably also important for cancer immunity. 
A subpopulation of these cells, iNKT cells, recognizes 
glycolipids presented by the nonpolymorphic CD1d 
antigen-presenting molecule [47]. These iNKT cells 
are capable of rapidly producing type Th1, Th2, and 
Th17 cytokines upon activation, as they store ready-
to-use cytokine mRNA. This shortens the route and 
time needed to cytokine production and release. The 
constant renewal, exchange, and activation of NKT 
cells may be maintained, as noted by several years of 
personal observations. These are induced by proper 
nutritional composition, containing lipids such as 
unsaturated fatty acids, omega-3, omega-6 lipids, and 
cod liver oil [46–50].
A system of vaccination, similar to ours, with autol-
ogous tumor cells for active specific immunotherapy, 
has also been presented by the other authors [51–54]. 
It seems that passive and active immunotherapy, 
supported by the additional activation of NKT cells, 
may help in preventing cancer in healthy persons, as 
well as curing for cancer patients.
In conclusion, the induction of apoptosis blocks 
cell proliferation. However, the apoptotic process, 
which takes about 2 h to complete once begun, is de-
layed by hours or days (4–5 days in irradiated B-CLL 
cells). Thus, the patient’s leukemia cells form heter-
ogenous population, as apoptosis starts at varius times 
after their induction in different cells. Vaccination 
with the actual cancer antigens of apoptosis-induced 
cells induces activation of several anticancer T cell 
clones. However, it was observed in B-CLL vacci-
nated patients that the response is blocked after 2–4 
months or more, which probably results from the 
physiological checkpoint regulation of immune system 
function; this is undesirable in cancer treatment. The 
anticancer vaccination should thus be followed by 
passive immunotherapy by treatment that prevents 
immune checkpoint blocking. Recently, anti-PD-1 
monoclonal antibodies, nivolumab (fully human IgG4 
antibody), and pembrolizumab (humanized IgG4-k 
antibody) have been approved for advanced kidney 
cancer [55, 56] and metastatic non-small-cell lung 
cancer (NSCLC), whose tumors express programmed 
death-ligand 1 (PD-L1) [54]. The treatment of B-CLL 
patients with anti-checkpoint blocker antibodies was 
unknown in 2003–2008 when we performed our study 
of apoptotic leukemia cell treatment in CLL patients. 
Since then, technological advances have led to the 
approval of immune checkpoint blocking monoclonal 
antibodies for the treatment of malignant lymphomas 
and B-CLL [57–60].
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